» Articles » PMID: 31005226

Pancreatic Cancer Treated with SBRT: Effect of Anatomical Interfraction Variations on Dose to Organs at Risk

Overview
Journal Radiother Oncol
Specialties Oncology
Radiology
Date 2019 Apr 22
PMID 31005226
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Interfraction shape and position variations of organs at risk (OARs) may increase uncertainty in dose delivery during stereotactic body radiotherapy (SBRT), potentially leading to overirradiation or concessions in planned tumor dose and/or coverage to prevent clinical constraints violation. The aim of our study was to quantitatively analyze the impact of anatomical interfraction variations on dose to OARs in pancreatic cancer (PC) treated by SBRT using a CyberKnife with integrated CT-on-rails.

Materials And Methods: Thirty-five PC patients treated with SBRT (40 Gy/5 fractions) underwent a CT-scan in treatment position before each of the first three fractions using the CT-on-rails system. OARs (stomach, duodenum, bowel) were manually delineated and concatenated to one structure (Gastro-Intestinal Organ, GIO). To overlay the planned dose distribution, fiducial-based alignment of the fraction CT with the planning CT was performed. Planned DVH parameters of the OAR were compared to the parameters calculated in the fractions CTs.

Results: Compared to the treatment plan, the median V35, D2, D5, D10 and Dmax of the fraction CTs in the GIO was increased by 1.0 (IQR: 0.2-2.6), 4.4% (0.4-10.8), 2.3% (0.2-7.5), 3.3% (-0.4 to 7.1), and 12.0% (5.0-18.9) respectively. Median increase was statistically significant for all parameters in GIO and for V35 in all critical structures at Wilcoxon test.

Conclusions: Anatomical interfraction variations increase OAR dose during SBRT for pancreatic cancer daily imaging using integrated CT/CyberKnife may allow to implement strategies to reduce the risk of OAR overirradiation during pancreatic SBRT.

Citing Articles

Dosimetric comparison of multiple SBRT delivery platforms for pancreatic cancer.

Song Y, Chen X, Yu X, Dong Y, Tian J, Wang X Eur J Med Res. 2024; 29(1):533.

PMID: 39497204 PMC: 11536576. DOI: 10.1186/s40001-024-02080-3.


Application of imaging technology for the diagnosis of malignancy in the pancreaticobiliary duodenal junction (Review).

Yang W, Hu P, Zuo C Oncol Lett. 2024; 28(6):596.

PMID: 39430731 PMC: 11487531. DOI: 10.3892/ol.2024.14729.


Pancreatic SABR using peritumoral fiducials, triggered imaging and breath-hold.

Kisivan K, Farkas A, Kovacs P, Glavak C, Lukacs G, Mahr K Pathol Oncol Res. 2024; 29:1611456.

PMID: 38188611 PMC: 10767757. DOI: 10.3389/pore.2023.1611456.


Predicting the daily gastrointestinal doses of stereotactic body radiation therapy for pancreatic cancer based on the shortest distance between the tumor and the gastrointestinal tract using daily computed tomography images.

Uchinami Y, Kanehira T, Nakazato K, Fujita Y, Koizumi F, Takahashi S BJR Open. 2023; 5(1):20230043.

PMID: 37942491 PMC: 10630971. DOI: 10.1259/bjro.20230043.


Analysis of the cost-effectiveness of proton beam therapy for unresectable pancreatic cancer in Japan.

Hiroshima Y, Kondo M, Sawada T, Hoshi S, Okubo R, Iizumi T Cancer Med. 2023; 12(20):20450-20458.

PMID: 37795771 PMC: 10652344. DOI: 10.1002/cam4.6611.